Pertuzumab: In the first-line treatment of HER2-positive metastatic breast cancer

Drugs

Volumn 72, Issue 3, 2012, Pages 353-360

  Keating, Gillian M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Drug Profiles; Breast cancer; Pertuzumab

Indexed keywords

DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PERTUZUMAB; PLACEBO; TRASTUZUMAB;

ADD ON THERAPY; ALOPECIA; ANEMIA; AREA UNDER THE CURVE; ASTHENIA; BREAST CANCER; BREAST METASTASIS; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CELL MEDIATED CYTOTOXICITY; CELL PROLIFERATION; CELL SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ASSESSMENT; CLINICAL TRIAL (TOPIC); CONSTIPATION; DECREASED APPETITE; DIARRHEA; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRY SKIN; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; GRANULOCYTOPENIA; HEART LEFT VENTRICLE FAILURE; HUMAN; LEUKOPENIA; LOADING DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; METASTATIC BREAST CANCER; MUCOSA INFLAMMATION; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PHARMACODYNAMICS; PHARMACOLOGICAL PARAMETERS; PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; REVIEW; SIGNAL TRANSDUCTION; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT RESPONSE; TUMOR XENOGRAFT;

ANTIBODIES, MONOCLONAL, HUMANIZED; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, ERBB-2; TREATMENT OUTCOME;

EID: 84856716249     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11209000-000000000-00000     Document Type: Review

References (33)

1. Agus DB, Akita RW, Fox WD, et al. Targeting ligandactivated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2002 Aug; 2 (2): 127-37 (Pubitemid 41039113)
2. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987 Jan 9; 235 (4785): 177-82 (Pubitemid 17231334)
3. Mé nard S, Tagliabue E, Campiglio M, et al. Role of HER2 gene overexpression in breast carcinoma. J Cell Physiol 2000 Feb; 182 (2): 150-62 (Pubitemid 30022667)
4. Gradishar WJ. HER2 therapy: an abundance of riches. N Engl J Med 2012 Jan 12; 366 (2): 176-8
5. Adams CW, Allison DE, Flagella K, et al. Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab. Cancer Immunol Immunother 2006 Jun; 55 (6): 717-27
6. Franklin MC, Carey KD, Vajdos FF, et al. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 2004 Apr; 5 (4): 317-28 (Pubitemid 38482068)
7. Scheuer W, Friess T, Burtscher H, et al. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res 2009 Dec 15; 69 (24): 9330-6
8. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: breast cancer (version2.2011) [online]. Available from URL http://www.nccn.org/professionals/physician-gls/pdf/breast.pdf [Accessed 2011 Dec 16]
9. Albanell J, Baselga J. Unraveling resistance to trastuzumab (Herceptin): insulin-like growth factor-I receptor, a new suspect. J Natl Cancer Inst 2001 Dec 19; 93 (24): 1830-2 (Pubitemid 34048643)
10. Agus DB, Gordon MS, Taylor C, et al. Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol 2005 Apr 10; 23 (11): 2534-43 (Pubitemid 47050843)
11. Baselga J, Swain SM. CLEOPATRA: a phase III evaluation of pertuzumab and trastuzumab for HER2-positive metastatic breast cancer. Clin Breast Cancer 2010 Dec 1; 10 (6): 489-91
12. Ng CM, Lum BL, Gimenez V, et al. Rationale for fixed dosing of pertuzumab in cancer patients based on population pharmacokinetic analysis. PharmRes 2006 Jun; 23 (6): 1275-84 (Pubitemid 43946149)
13. Totpal K, Balter I, Akita RW, et al. Targeting ErbB2/HER2's role as a coreceptor with rhuMAb2C4 inhibits Erb/HER ligand-dependent signaling and poliferation of ovarian tumor cell lines [abstract no. 776]. Proc Am Assoc Cancer Res 2003 Jul; 44: 151
14. Lewis GD, Lofgren JA, McMurtrey AE, et al. Growth regulation of human breast and ovarian tumor cells by heregulin: evidence for the requirement of ErbB2 as a critical component in mediating heregulin responsiveness. Cancer Res 1996 Mar 15; 56 (6): 1457-65 (Pubitemid 26080994)
15. Malik MA, Totpal K, Balter I, et al. Dose-response studies of recombinant humanized monoclonal antibody 2C4 in tumor xenograft models [abstract no. 773]. Proc Am Assoc Cancer Res 2003 Jul; 44: 150
16. Lee-Hoeflich ST, Crocker L, Yao E, et al. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res 2008 Jul 15; 68 (14): 5878-87
17. Schaefer G, Fitzpatrick VD, Sliwkowski MX. g-Heregulin: a novel heregulin isoform that is an autocrine growth factor for the human breast cancer cell line, MDA-MB-175. Oncogene 1997 Sep 18; 15 (12): 1385-94 (Pubitemid 27437828)
18. Mendoza N, Phillips GL, Silva J, et al. Inhibition of ligandmediated HER2 activation in androgen-independent prostate cancer. Cancer Res 2002 Oct 1; 62 (19): 5485-8
19. Liu J, Kern JA. Neuregulin-1 activates the JAK-STAT pathway and regulates lung epithelial cell proliferation. Am J Respir Cell Mol Biol 2002 Sep; 27 (3): 306-13 (Pubitemid 34979288)
20. Friess T, Bauer S, Burger AM, et al. In vivo activity of recombinant humanized monoclonal antibody 2C4 in xenografts is independent of tumor type and degree of HER2 overexpression [abstract no. 496]. Eur J Cancer 2002 Nov; 38 Suppl. 7: 149
21. Bossenmaier B, Hasmann M, Koll H, et al. Presence of HER2/HER3 heterodimers predicts antitumor effects of pertuzumab (Omnitarg) in different human xenograft models [abstract no. 5342]. Proc Am Assoc Cancer Res 2004; 45: 1232
22. Mann M, Sheng H, Shao J, et al. Targeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth. Gastroenterology 2001 Jun; 120 (7): 1713-9 (Pubitemid 32523489)
23. Gianni L, Lladó A, Bianchi G, et al. Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2010 Mar 1; 28 (7): 1131-7
24. Nahta R, Hung M-C, Esteva FJ. The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res 2004 Apr 1; 64 (7): 2343-6 (Pubitemid 38523885)
25. Yamamoto N, Yamada Y, Fujiwara Y, et al. Phase I and pharmacokinetic study of HER2-targeted rhuMAb 2C4 (Pertuzumab, RO4368451) in Japanese patients with solid tumors. Jpn J Clin Oncol 2009; 39 (4): 260-6
26. Attard G, Kitzen J, Blagden SP, et al. A phase Ib study of pertuzumab, a recombinant humanised antibody to HER2, and docetaxel in patients with advanced solid tumours. Br J Cancer 2007; 97 (10): 1338-43 (Pubitemid 350114792)
27. Baselga J, Corté s J, Kim S-B, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012 Jan 12; 366 (2): 109-19
28. Portera CC, Walshe JM, Rosing DR, et al. Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with trastuzumab-insensitive human epidermal growth factor receptor 2-positive metastatic breast cancer. Clin Cancer Res 2008 May 1; 14 (9): 2710-6
29. Baselga J, Gelmon KA, Verma S, et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol 2010 Mar 1; 28 (7): 1138-44
30. Ellis PA, Barrios CH, Im Y, et al. MARIANNE: a phase III, randomized study of trastuzumab-DM1 (T-DM1) with or without pertuzumab (P) compared with trastuzumab (H) plus taxane for first-line treatment of HER2-positive, progressive, or recurrent locally advanced or metastatic breast cancer (MBC) [abstract no. TPS102]. 47th Annual Meeting of the American Society of Clinical Oncology; 2011 Jun 3-7; Chicago (IL)
31. Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 2012 Jan; 13 (1): 25-32
32. Schneeweiss A, Chia S, Hickish T, et al. Neoadjuvant pertuzumab and trastuzumab concurrent or sequential with an anthracycline-containing or concurrent with an anthracycline- free standard regimen: a randomized phase II study (TRYPHAENA) [abstract no. S5-6]. Cancer Res 2011 Dec 15; 71 (24 Suppl.): 112S
33. von Minckwitz G, Baselga J, Bradbury I, et al. Adjuvant pertuzumab and Herceptin in initial therapy of breast cancer: APHINITY [abstract no. OT1-02-04]. Cancer Res 2011 Dec 15; 71 (24 Suppl.): 602S